Literature DB >> 25795393

Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis.

D Subirá1, M Simó, J Illán, C Serrano, S Castañón, R Gonzalo, J J Granizo, M Martínez-García, M Navarro, J Pardo, J Bruna.   

Abstract

Some patients with epithelial-cell cancers develop leptomeningeal carcinomatosis (LC), a severe complication difficult to diagnose and with an adverse prognosis. This study explores the contribution of flow cytometry immunophenotyping (FCI) to the diagnosis and prognosis of LC. Cerebrospinal fluid (CSF) samples from patients diagnosed with LC were studied using FCI. Expression of the epithelial-cell adhesion molecule (EpCAM) was the criterion used to identify the epithelial cells. To test the diagnostic precision, 144 patients (94 diagnosed with LC) were included. The prognostic value of FCI was evaluated in 72 patients diagnosed with LC and eligible for therapy. Compared with cytology, FCI showed greater sensitivity and negative predictive value (79.79 vs. 50%; 68.85 vs. 51.55%, respectively), but lower specificity and positive predictive value (84 vs. 100%; 90.36 vs. 100%, respectively). The multivariate analysis revealed that the percentage of CSF EpCAM+ cells predicted an increased risk of death (HR: 1.012, 95% CI 1.000-1.023; p=0.041). A cut-off value of 8% EpCAM+ cells in the CSF distinguished two groups of patients with statistically significant differences in overall survival (OS) (p=0.018). This cut-off value kept its statistical significance regardless of the absolute CSF cell-count. The FCI study of the CSF improved the sensitivity for diagnosing LC, but refinement of the technique is needed to improve specificity. Furthermore, quantification of CSF EpCAM+ cells was revealed to be an independent prognostic factor for OS in patients with LC eligible for therapy. An 8% cut-off value contributed to predicting clinical evolution before initiation of therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25795393     DOI: 10.1007/s10585-015-9716-3

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  35 in total

1.  Survival of breast cancer patients with meningeal carcinomatosis.

Authors:  H Gauthier; M N Guilhaume; F C Bidard; J Y Pierga; V Girre; P H Cottu; V Laurence; A Livartowski; L Mignot; V Diéras
Journal:  Ann Oncol       Date:  2010-04-29       Impact factor: 32.976

2.  Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis.

Authors:  Karin Oechsle; Victoria Lange-Brock; Andreas Kruell; Carsten Bokemeyer; Maike de Wit
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-04       Impact factor: 4.553

3.  An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions.

Authors:  Nektaria A Kentrou; Nikolaos J Tsagarakis; Konstantina Tzanetou; Maria Damala; Konstantinos A Papadimitriou; Dimitra Skoumi; Aimilia Stratigaki; Nikolaos I Anagnostopoulos; Eleni Malamou-Lada; Pauline Athanassiadou; George Paterakis
Journal:  Cytometry B Clin Cytom       Date:  2011-06-21       Impact factor: 3.058

4.  High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.

Authors:  Upendra Hegde; Armando Filie; Richard F Little; John E Janik; Nicole Grant; Seth M Steinberg; Kieron Dunleavy; Elaine S Jaffe; Andrea Abati; Maryalice Stetler-Stevenson; Wyndham H Wilson
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

5.  Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.

Authors:  Morris D Groves; Kenneth R Hess; Vinay K Puduvalli; Howard Colman; Charles A Conrad; Mark R Gilbert; Jeffrey Weinberg; Massimo Cristofanilli; W K Alfred Yung; Ta-Jen Liu
Journal:  J Neurooncol       Date:  2009-03-07       Impact factor: 4.130

6.  Neoplastic meningitis-related prognostic significance of the Karnofsky performance status.

Authors:  Marc C Chamberlain; Sandra K Johnston; Mike J Glantz
Journal:  Arch Neurol       Date:  2009-01

7.  Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination.

Authors:  Giulia Benevolo; Alessandra Stacchini; Michele Spina; Andrés J M Ferreri; Marcella Arras; Laura Bellio; Barbara Botto; Pietro Bulian; Maria Cantonetti; Lorella Depaoli; Nicola Di Renzo; Alice Di Rocco; Andrea Evangelista; Silvia Franceschetti; Laura Godio; Francesco Mannelli; Vincenzo Pavone; Pietro Pioltelli; Umberto Vitolo; Enrico M Pogliani
Journal:  Blood       Date:  2012-08-27       Impact factor: 22.113

Review 8.  Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe.

Authors:  Michael W Klymkowsky; Pierre Savagner
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

9.  Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases.

Authors:  Akshal S Patel; Joshua E Allen; David T Dicker; Kristi L Peters; Jonas M Sheehan; Michael J Glantz; Wafik S El-Deiry
Journal:  Oncotarget       Date:  2011-10

10.  Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer.

Authors:  I Songun; S V Litvinov; C J H van de Velde; S T Pals; J Hermans; J H J M van Krieken
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

View more
  15 in total

1.  SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis).

Authors:  Chanida Vinayanuwattikun; Siyamol Mingmalairak; Nutchawan Jittapiromsak; Iyavut Thaipisuttikul; Virote Sriuranpong; Apiwat Mutirangura; Shanop Shuangshoti
Journal:  J Neurooncol       Date:  2016-07-11       Impact factor: 4.130

Review 2.  Leptomeningeal Metastases.

Authors:  Jerome J Graber; Santosh Kesari
Journal:  Curr Treat Options Oncol       Date:  2018-01-23

Review 3.  Breast leptomeningeal disease: a review of current practices and updates on management.

Authors:  Nicholas B Figura; Victoria T Rizk; Avan J Armaghani; John A Arrington; Arnold B Etame; Hyo S Han; Brian J Czerniecki; Peter A Forsyth; Kamran A Ahmed
Journal:  Breast Cancer Res Treat       Date:  2019-06-17       Impact factor: 4.872

Review 4.  Novel methods to diagnose leptomeningeal metastases in breast cancer.

Authors:  Lindsay Angus; John W M Martens; Martin J van den Bent; Peter A E Sillevis Smitt; Stefan Sleijfer; Agnes Jager
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

Review 5.  Leptomeningeal metastases: a RANO proposal for response criteria.

Authors:  Marc Chamberlain; Larry Junck; Dieta Brandsma; Riccardo Soffietti; Roberta Rudà; Jeffrey Raizer; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Julie Walker; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

6.  Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ Assay.

Authors:  Margaux Wooster; Julia E McGuinness; Kathleen M Fenn; Veena M Singh; Lauren E Franks; Shing Lee; David Cieremans; Andrew B Lassman; Dawn L Hershman; Katherine D Crew; Melissa K Accordino; Meghna S Trivedi; Fabio Iwamoto; Mary R Welch; Aya Haggiagi; Robbie D Schultz; Lan Huynh; Edgar Sales; Deanna Fisher; Julie Ann Mayer; Teri Kreisl; Kevin Kalinsky
Journal:  Clin Breast Cancer       Date:  2021-11-14       Impact factor: 3.078

7.  EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors.

Authors:  Bojana Milojkovic Kerklaan; Dick Pluim; Mijke Bol; Ingrid Hofland; Johan Westerga; Harm van Tinteren; Jos H Beijnen; Willem Boogerd; Jan H M Schellens; Dieta Brandsma
Journal:  Neuro Oncol       Date:  2015-11-12       Impact factor: 12.300

Review 8.  EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

Authors:  Mark T J van Bussel; Dick Pluim; Mijke Bol; Jos H Beijnen; Jan H M Schellens; Dieta Brandsma
Journal:  J Neurooncol       Date:  2017-11-30       Impact factor: 4.130

9.  Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.

Authors:  Xuling Lin; Martin Fleisher; Marc Rosenblum; Oscar Lin; Adrienne Boire; Samuel Briggs; Yevgeniya Bensman; Brenda Hurtado; Larisa Shagabayeva; Lisa M DeAngelis; Katherine S Panageas; Antonio Omuro; Elena I Pentsova
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

10.  Gadobutrol-enhanced magnetic resonance imaging of meningeal carcinomatosis: case report with emphasis on early diagnosis.

Authors:  Xinfa Pan; Yongfu Lu; Liang Wen; Xiujue Zheng; Yuehui Ma
Journal:  BMC Neurol       Date:  2016-09-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.